

Considerations for Writing Specialty Pharmacy Prescriptions for LEQVIO®

When you are acquiring LEQVIO through a specialty pharmacy, it is important to ensure that the prescription is written completely and accurately. Your prescription may be rejected if it is incorrectly written.

Please see below for some considerations on how you may write the two prescriptions for LEQVIO.

This information is provided for educational purposes only. It is not meant to be exhaustive of all information that may need to be considered when writing a prescription. It is the sole responsibility of the health care provider to ensure the accuracy of all statements and information included in the prescription for an individual patient.



Prescription #1: Initial Doses (Day 0 and Day 90)

Dose Type	284 mg/1.5 mL (189 mg/mL) in a single-dose prefilled syringe
Quantity	1
Refill	1
Administration	<ul style="list-style-type: none">• HCP to inject inclisiran subcutaneously into the abdomen, upper arm, or thigh• HCP to administer initially and again at 3 months

Prescription #2: Maintenance Doses (Every 6 Months After the First 2 Doses)

Dose Type	284 mg/1.5 mL (189 mg/mL) in a single-dose prefilled syringe
Quantity	1
Refill	1
Administration	<ul style="list-style-type: none">• HCP to inject inclisiran subcutaneously into the abdomen, upper arm, or thigh• HCP to administer every 6 months after the first two doses

Please refer to the LEQVIO full Prescribing Information for dosing information.

Remember, some specialty pharmacies may accept slight variations of the prescription. It is important to contact your specialty pharmacy and confirm their guidelines for how to appropriately write a prescription for LEQVIO.

If you have additional questions, please reach out to your Novartis Access and Reimbursement Expert.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH), and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

IMPORTANT SAFETY INFORMATION

Contraindication: LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with LEQVIO. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly.

Adverse Reactions: Adverse reactions in clinical trials ($\geq 3\%$ of adult patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis. The safety profile in pediatric patients aged 12 years and older with HeFH or HoFH was consistent with adult patients with hypercholesterolemia, except for a higher frequency of headache in pediatric patients with HeFH.

Please click [here](#) for LEQVIO full Prescribing Information.

Licensed from Alnylam Pharmaceuticals, Inc.

